



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Attorney Docket No. AM100878-P1)

In re Patent Application of: ) Appln. No.: 10/808,964  
 ) Confirmation No.: 7042  
XIANG-JIN MENG *et al.* ) Customer No.: 000044091  
 ) Group Art Unit: 1648  
Filed: 03/25/2004 ) Examiner: Stacy Brown Chen  
 )  
For: CHIMERIC INFECTIOUS DNA CLONES, )  
CHIMERIC PORCINE CIRCOVIRUSES )  
AND USES THEREOF ) Paper No.: 17

AMENDMENT

Dear Sir:

Responsive to the Official action mailed February 16, 2006, please amend the above-referenced patent application using the below instructions and consider the remarks in a favorable light.

REMARKS

Reconsideration of this application, as amended, is respectfully requested.

In accord with 37 C.F.R. § 1.121, the amendment to the claims including a complete listing of all pending claims begin on a separate sheet. As required, only the claim number and status indicate any canceled claims. The amendment adds no new matter into the application. For the convenience of the Office staff, this amendment is placed in the below Appendix and incorporated herein by reference thereto.

To expedite matters, the present amendment cancels non-elected Claim 31 (Group VI) without prejudice to filing a divisional application directed to its subject matter. While non-elected Claims 23-28 (Group V) have been withdrawn from consideration, they are retained in this response to provide the Examiner the opportunity to rejoin the process claims with the allowable product claims. New Claims 33-38 have been added to encompass the vaccine and its method of use in which the vaccine comprises a nontoxic, physiologically acceptable carrier and an immunogenic amount of the chimeric nucleic acid molecule of PCV1-2 corresponding to the scope of the elected, allowed subject matter of Claims 1-3. The new claims find support in the specification on page 17, lines 14-31 and elsewhere.